The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising. In light of the stark unmet needs in liver disease treatment — particularly for metabolic dysfunction-associated steatohepatitis (MASH) — there’s a pressing need for more sites equipped to effectively support advanced liver disease research.
As Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, mentions in this video, there’s reason to be optimistic if we can carry momentum from the recent hepatology breakthroughs further into MASH treatment. With the expertise of renowned investigators like Dr. Kowdley and Nadege Gunn, MD, CPI, Velocity’s MASH Council to Accelerate Research Excellence (CARE) will deliver world-class operational, recruitment, and trial conduct oversight to all Velocity sites conducting MASH trials.
